Celldex Therapeutics, Inc. (CLDX)’s Stock Is Sell After Reaching 1 Year Low

April 16, 2018 - By Adrian Erickson

The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) hit a new 52-week low and has $0.71 target or 9.00 % below today’s $0.79 share price. The 5 months bearish chart indicates high risk for the $110.74M company. The 1-year low was reported on Apr, 16 by Barchart.com. If the $0.71 price target is reached, the company will be worth $9.97 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 63.49% or $1.365 during the last trading session, reaching $0.785. About 18.91 million shares traded or 1237.92% up from the average. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 30.36% since April 16, 2017 and is downtrending. It has underperformed by 41.91% the S&P500.

Analysts await Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report earnings on May, 8. They expect $-0.18 EPS, up 35.71 % or $0.10 from last year’s $-0.28 per share. After $-0.17 actual EPS reported by Celldex Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.88 % negative EPS growth.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Among 4 analysts covering Celldex (NASDAQ:CLDX), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Celldex had 4 analyst reports since November 7, 2017 according to SRatingsIntel. The stock has “Buy” rating by WBB Securities on Wednesday, December 6. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, November 7 report. The firm earned “Market Perform” rating on Thursday, March 8 by Leerink Swann. Jefferies maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) rating on Thursday, March 8. Jefferies has “Hold” rating and $3.0 target.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $110.74 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. It currently has negative earnings. The firm also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.